tetano
Editor, Senior Moderator
J Clin Virol. 2020 Apr 9;127:104364. doi: 10.1016/j.jcv.2020.104364. [Epub ahead of print]
Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.
Zhang G[SUP]1[/SUP], Hu C[SUP]2[/SUP], Luo L[SUP]3[/SUP], Fang F[SUP]4[/SUP], Chen Y[SUP]5[/SUP], Li J[SUP]2[/SUP], Peng Z[SUP]2[/SUP], Pan H[SUP]6[/SUP].
Author information
Abstract
BACKGROUND:
In late December 2019, an outbreak of acute respiratory illness, coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. We aimed to study the epidemiology, clinical features and short-term outcomes of patients with COVID-19 in Wuhan, China.
METHODS:
We performed a single center, retrospective case series study in 221 patients with laboratory confirmed SARS-CoV-2 pneumonia at a university hospital, including 55 severe patients and 166 non-severe patients, from January 2, 2020 to February 10, 2020.
RESULTS:
Of the 221 patients with COVID-19, the median age was 55.0 years and 48.9% were male and only 8 (3.6%) patients had a history of exposure to the Huanan Seafood Market. Compared to the non-severe pneumonia patients, the median age of the severe patients was significantly older, and they were more likely to have chronic comorbidities. Most common symptoms in severe patients were high fever, anorexia and dyspnea. On admission, 33.0% patients showed leukopenia and 73.8% showed lymphopenia. In addition, the severe patients suffered a higher rate of co-infections with bacteria or fungus and they were more likely to developing complications. As of February 15, 2020, 19.0% patients had been discharged and 5.4% patients died. 80% of severe cases received ICU (intensive care unit) care, and 52.3% of them transferred to the general wards due to relieved symptoms, and the mortality rate of severe patients in ICU was 20.5%.
CONCLUSIONS:
Patients with elder age, chronic comorbidities, blood leukocyte/lymphocyte count, procalcitonin level, co-infection and severe complications might increase the risk of poor clinical outcomes.
Copyright ? 2020 Elsevier B.V. All rights reserved.
PMID:32311650DOI:10.1016/j.jcv.2020.104364
Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.
Zhang G[SUP]1[/SUP], Hu C[SUP]2[/SUP], Luo L[SUP]3[/SUP], Fang F[SUP]4[/SUP], Chen Y[SUP]5[/SUP], Li J[SUP]2[/SUP], Peng Z[SUP]2[/SUP], Pan H[SUP]6[/SUP].
Author information
Abstract
BACKGROUND:
In late December 2019, an outbreak of acute respiratory illness, coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. We aimed to study the epidemiology, clinical features and short-term outcomes of patients with COVID-19 in Wuhan, China.
METHODS:
We performed a single center, retrospective case series study in 221 patients with laboratory confirmed SARS-CoV-2 pneumonia at a university hospital, including 55 severe patients and 166 non-severe patients, from January 2, 2020 to February 10, 2020.
RESULTS:
Of the 221 patients with COVID-19, the median age was 55.0 years and 48.9% were male and only 8 (3.6%) patients had a history of exposure to the Huanan Seafood Market. Compared to the non-severe pneumonia patients, the median age of the severe patients was significantly older, and they were more likely to have chronic comorbidities. Most common symptoms in severe patients were high fever, anorexia and dyspnea. On admission, 33.0% patients showed leukopenia and 73.8% showed lymphopenia. In addition, the severe patients suffered a higher rate of co-infections with bacteria or fungus and they were more likely to developing complications. As of February 15, 2020, 19.0% patients had been discharged and 5.4% patients died. 80% of severe cases received ICU (intensive care unit) care, and 52.3% of them transferred to the general wards due to relieved symptoms, and the mortality rate of severe patients in ICU was 20.5%.
CONCLUSIONS:
Patients with elder age, chronic comorbidities, blood leukocyte/lymphocyte count, procalcitonin level, co-infection and severe complications might increase the risk of poor clinical outcomes.
Copyright ? 2020 Elsevier B.V. All rights reserved.
PMID:32311650DOI:10.1016/j.jcv.2020.104364